Background The increasing use of highly active antiretroviral therapy (HAART) and
pneumococcal immunization along with shifting community exposures may have altered the …

It is unclear whether HIV-infected individuals remain at higher risk of invasive pneumococcal
disease (IPD) compared with HIV-uninfected individuals. We conducted a cohort study of …

Objectives: To examine invasive pneumococcal disease (IPD) incidence, the impact of the 7-
valent pneumococcal conjugate vaccines (PCV7s) programme on the distribution of …

We studied all human immunodeficiency virus (HIV)-infected patients with invasive
pneumococcal disease who received their diagnosis during 1996–2002 to investigate the …

Objectives The aim of the study was to describe trends and risk factors for mortality and
changes in antibiotic resistance, serotypes and clones among HIV‐infected patients with …

Background. Invasive pneumococcal disease (IPD) is an important cause of morbidity
among individuals infected with human immunodeficiency virus (HIV). We described …

Objective: To investigate the association between the introduction of HAART and invasive
pneumococcal disease (IPD) in HIV-infected patients. Methods: Incidence of IPD was …

Background Highly active antiretroviral treatment (HAART) programs have been associated
with declines in the burden of invasive pneumococcal disease (IPD) in industrialized …

Background. Human immunodeficiency virus (HIV)—infected persons have a high incidence
of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent …

Background Although people living with human immunodeficiency virus (PLWH) are at
increased risk of invasive pneumococcal disease (IPD) and community-acquired pneumonia …